113 related articles for article (PubMed ID: 31646809)
1. Ultrasound combined with computed tomography in pancreatic cancer.
Liu L; Huang X; Li X; Ma L; Zhao X; Yang X
J BUON; 2019; 24(4):1562-1567. PubMed ID: 31646809
[TBL] [Abstract][Full Text] [Related]
2. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
3. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
4. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
5. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
[TBL] [Abstract][Full Text] [Related]
6. Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites.
Liu J; Liu G; Liu X; Zhu X; Wang Y; Gou B; You L
Cancer Biother Radiopharm; 2019 Apr; 34(3):203-207. PubMed ID: 30585766
[TBL] [Abstract][Full Text] [Related]
7. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
8. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
Sun Y; Duan Q; Wang S; Zeng Y; Wu R
J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
[TBL] [Abstract][Full Text] [Related]
11. Negative predictive value of positron emission tomography/computed tomography in patients with a clinical suspicion of pancreatic cancer.
Lin JL; Barthel JS; Keshishian J; Eikman EA; Klapman JB
Pancreas; 2011 Jul; 40(5):653-6. PubMed ID: 21602734
[TBL] [Abstract][Full Text] [Related]
12. Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions--a comparison of conventional ultrasound and contrast-enhanced CT.
Fan Z; Li Y; Yan K; Wu W; Yin S; Yang W; Xing B; Li X; Zhang X
Eur J Radiol; 2013 Sep; 82(9):1385-90. PubMed ID: 23727375
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
[TBL] [Abstract][Full Text] [Related]
14. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions.
Papós M; Takács T; Trón L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Pávics L
Clin Nucl Med; 2002 Mar; 27(3):197-201. PubMed ID: 11852308
[TBL] [Abstract][Full Text] [Related]
15. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
16. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.
Tang S; Huang G; Liu J; Liu T; Treven L; Song S; Zhang C; Pan L; Zhang T
Eur J Radiol; 2011 Apr; 78(1):142-50. PubMed ID: 19854016
[TBL] [Abstract][Full Text] [Related]
18. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases.
Sánchez-Bueno F; García-Pérez R; Claver Valderas MA; de la Peña Moral J; Frutos Esteban L; Ortiz Ruiz E; Fuster Quiñonero M; Parrilla Paricio P
Cir Esp; 2016 Nov; 94(9):511-517. PubMed ID: 27712835
[TBL] [Abstract][Full Text] [Related]
19. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
20. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
